Professor NIKOLA SPRIGG nikola.sprigg@nottingham.ac.uk
PROFESSOR OF STROKE MEDICINE
Results from the tranexamic acid for primary intracerebral haemorrhage-2 (TICH-2) trial
Sprigg, Nikola; Flaherty, Katie; Law, Zhe Kang; Appleton, Jason P.; Scutt, Polly; Krishnan, Kailash; Bath, Philip M.
Authors
Katie Flaherty
Zhe Kang Law
Jason P. Appleton
Polly Scutt
Kailash Krishnan
Professor PHILIP BATH philip.bath@nottingham.ac.uk
STROKE ASSOCIATION PROFESSOR OF STROKE MEDICINE
Abstract
Background: Haematoma expansion leads to worse outcome in intracerebral haemorrhage (ICH). Tranexamic acid (TXA) is a promising haemostatic agent to prevent haematoma expansion and improve outcome after ICH.
Methods: TICH-2 is a multicentre prospective double blind randomised controlled trial, which recruited patients presenting within 8 hours of primary ICH to receive intravenous TXA or placebo. Primary outcome is modified Rankin Scale at day 90 and will be analysed using ordinal logistic regression, adjusted for minimisation criteria. Secondary outcomes will be analysed using adjusted binary logistic regression and multiple linear regression; these include haematoma expansion at 24 hours, day 7 National Institute of Health Stroke Scale (NIHSS), day 90 Barthel Index, quality of life, cognition and mood.
Results: A total of 2325 patients were recruited between 14th March 2013 and 30th September 2017, from 12 countries: United Kingdom (n= 1910), Italy, Georgia, Switzerland, Malaysia, Hungary, Poland, Ireland, Turkey, Sweden, Denmark and Spain. Randomisation characteristics included: age 68.9 (13.8) years; male 1301 (56.0%); time from onset to randomisation 3.6 hours [2.6, 5.0]; NIHSS 13 (7.5); Glasgow coma scale 13.4 (2.1); systolic blood pressure 172.6 (27.2) mmHg; intraventricular haemorrhage 745 (32.0%) and prior antiplatelet use 610 (26.2%).
Conclusion: TICH-2 is the largest trial of TXA in spontaneous ICH and recruited over its original target of 2000 patients. The results will be available in May 2018 and will inform whether TXA should be recommended for the treatment of acute spontaneous ICH.
Citation
Sprigg, N., Flaherty, K., Law, Z. K., Appleton, J. P., Scutt, P., Krishnan, K., & Bath, P. M. Results from the tranexamic acid for primary intracerebral haemorrhage-2 (TICH-2) trial. Presented at 4th European Stroke Organisation Conference (ESOC 2018)
Conference Name | 4th European Stroke Organisation Conference (ESOC 2018) |
---|---|
End Date | May 18, 2018 |
Acceptance Date | Feb 25, 2018 |
Publication Date | May 16, 2018 |
Deposit Date | Apr 13, 2018 |
Publicly Available Date | May 16, 2018 |
Peer Reviewed | Peer Reviewed |
Public URL | https://nottingham-repository.worktribe.com/output/932557 |
Contract Date | Apr 13, 2018 |
Files
TICH-2 main results ESOC 2018 V41.pdf
(78 Kb)
PDF
You might also like
Influence of Time to Achieve Target Systolic Blood Pressure on Outcome after Intracerebral Hemorrhage: The Blood Pressure in Acute Stroke Collaboration
(2024)
Presentation / Conference Contribution
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search